Moneycontrol PRO

Cipla: Focus shifts to FY23 launches

In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch

October 27, 2021 / 10:42 AM IST
Cipla: Focus shifts to FY23 launches

Robust volumes were witnessed in trade generic business as well as consumer health business in India.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Cipla (CMP: Rs 908; Market Cap: Rs 73,200 crore), along with the pharma sector, has consolidated in the last five months almost in sync with the tapering of COVID opportunity. New headwinds, such as commodity inflation and elevated pricing erosion, have also emerged. We believe the sector is ripe for differentiation in terms of product launches and transition to a post-COVID  business scenario. Given this background, we take a closer look at the recent management commentary, post the results, and the...

  • PRO Panorama

    Moneycontrol Pro Panorama | Auto sales are running out of fuel

    Dec 2, 2021 / 02:45 PM IST

    In today’s edition of Moneycontrol Pro Panorama: The metal play, Anand Rathi IPO gets off the block, decoding Digital Banks, Start-up Street, Rahul Dravid faces a tall order, Lex-speak and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | The Harder They Fall 

    Nov 27, 2021 / 10:05 AM IST

    It’s early days yet, but stock investors are selling first and asking questions later

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers